These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38515335)

  • 1. Long-term cost-effectiveness of transcatheter mitral valve repair in  HF patients with secondary mitral regurgitation.
    Yao Y; Zhou Z; Geng T; Cai A; Li T; Yang J; Chen J; Li L
    ESC Heart Fail; 2024 Aug; 11(4):2023-2032. PubMed ID: 38515335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial.
    Baron SJ; Wang K; Arnold SV; Magnuson EA; Whisenant B; Brieke A; Rinaldi M; Asgar AW; Lindenfeld J; Abraham WT; Mack MJ; Stone GW; Cohen DJ;
    Circulation; 2019 Dec; 140(23):1881-1891. PubMed ID: 31564137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation.
    Cameron HL; Bernard LM; Garmo VS; Hernandez JB; Asgar AW
    J Med Econ; 2014 Aug; 17(8):599-615. PubMed ID: 24826880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients.
    Vemulapalli S; Lippmann SJ; Krucoff M; Hernandez AF; Curtis LH; Foster E; Qasim A; Wang A; Glower DD; Feldman T; Hammill BG
    Am Heart J; 2017 Jul; 189():146-157. PubMed ID: 28625371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial.
    Mack MJ; Abraham WT; Lindenfeld J; Bolling SF; Feldman TE; Grayburn PA; Kapadia SR; McCarthy PM; Lim DS; Udelson JE; Zile MR; Gammie JS; Gillinov AM; Glower DD; Heimansohn DA; Suri RM; Ellis JT; Shu Y; Kar S; Weissman NJ; Stone GW
    Am Heart J; 2018 Nov; 205():1-11. PubMed ID: 30134187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK.
    Shore J; Russell J; Frankenstein L; Candolfi P; Green M
    J Med Econ; 2020 Dec; 23(12):1425-1434. PubMed ID: 33236939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter Mitral Valve Repair in Patients With and Without Cardiac Resynchronization Therapy: The COAPT Trial.
    Kosmidou I; Lindenfeld J; Abraham WT; Kar S; Lim DS; Mishell JM; Whisenant BK; Kipperman RM; Boudoulas KD; Redfors B; Shahim B; Zhang Z; Mack MJ; Stone GW
    Circ Heart Fail; 2020 Nov; 13(11):e007293. PubMed ID: 33176460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the MitraClip device in German heart failure patients with secondary mitral regurgitation.
    Estler B; Rudolph V; Seleznova Y; Shukri A; Stock S; Müller D
    Eur J Health Econ; 2023 Apr; 24(3):349-358. PubMed ID: 35622185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of percutaneous mitral valve repair in inoperable patients with functional mitral regurgitation in German settings.
    Borisenko O; Haude M; Hoppe UC; Siminiak T; Lipiecki J; Goldberg SL; Mehta N; Bouknight OV; Bjessmo S; Reuter DG
    BMC Cardiovasc Disord; 2015 May; 15():43. PubMed ID: 25971307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation.
    Armeni P; Boscolo PR; Tarricone R; Capodanno D; Maggioni AP; Grasso C; Tamburino C; Maisano F
    Int J Cardiol; 2016 Apr; 209():153-60. PubMed ID: 26894467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and economic impact of transcatheter mitral leaflet repair in heart failure patients.
    Asgar AW; Khairy P; Guertin MC; Cournoyer D; Ducharme A; Bonan R; Basmadjian A; Tardif JC; Cohen DJ
    J Med Econ; 2017 Jan; 20(1):82-90. PubMed ID: 27552378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation.
    Cohen DJ; Wang K; Magnuson E; Smith R; Petrie MC; Buch MH; Abraham W; Lindenfeld J; Mack MJ; Stone GW; Cleland JGF
    Heart; 2022 May; 108(9):717-724. PubMed ID: 35078867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of percutaneous mitral valve repair with the MitraClip delivery system for patients with mitral regurgitation in Japan.
    Sakamaki H; Nakao K; Matsumoto T; Inoue S
    J Med Econ; 2019 Dec; 22(12):1312-1320. PubMed ID: 31516049
    [No Abstract]   [Full Text] [Related]  

  • 14. Repeat Mitral Valve Interventions After Transcatheter Edge-to-Edge Repair: The COAPT Trial.
    Shahim B; Cohen DJ; Asch FM; Bax J; George I; Rück A; Ben-Yehuda O; Kar S; Lim DS; Saxon JT; Zhou Z; Lindenfeld J; Abraham WT; Mack MJ; Stone GW
    Am J Cardiol; 2024 Jul; 223():7-14. PubMed ID: 38788821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Mitral Valve Repair Versus Replacement for Severe Ischemic Mitral Regurgitation: A Randomized Clinical Trial From the Cardiothoracic Surgical Trials Network.
    Ferket BS; Ailawadi G; Gelijns AC; Acker M; Hohmann SF; Chang HL; Bouchard, D; Meltzer DO; Michler RE; Moquete EG; Voisine P; Mullen JC; Lala A; Mack MJ; Gillinov AM; Thourani VH; Miller MA; Gammie JS; Parides MK; Bagiella E; Smith RL; Smith PK; Hung JW; Gupta LN; Rose EA; O'Gara PT; Moskowitz AJ; Cardiothoracic Surgical Trials Network (CTSN) Investigators
    Circ Cardiovasc Qual Outcomes; 2018 Nov; 11(11):e004466. PubMed ID: 30785252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Peripheral Artery Disease in Patients With Heart Failure Undergoing Transcatheter Mitral Valve Repair: The COAPT Trial.
    Shahim B; Cohen DJ; Ben-Yehuda O; Redfors B; Kar S; Lim DS; Arnold SV; Li Y; Lindenfeld J; Abraham WT; Mack MJ; Stone GW
    J Am Heart Assoc; 2023 Feb; 12(4):e028444. PubMed ID: 36752227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial.
    Giustino G; Camaj A; Kapadia SR; Kar S; Abraham WT; Lindenfeld J; Lim DS; Grayburn PA; Cohen DJ; Redfors B; Zhou Z; Pocock SJ; Asch FM; Mack MJ; Stone GW
    J Am Coll Cardiol; 2022 Nov; 80(20):1857-1868. PubMed ID: 36357085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary Hypertension in Transcatheter Mitral Valve Repair for Secondary Mitral Regurgitation: The COAPT Trial.
    Ben-Yehuda O; Shahim B; Chen S; Liu M; Redfors B; Hahn RT; Asch FM; Weissman NJ; Medvedofsky D; Puri R; Kapadia S; Sannino A; Grayburn P; Kar S; Lim S; Lindenfeld J; Abraham WT; Mack MJ; Stone GW
    J Am Coll Cardiol; 2020 Dec; 76(22):2595-2606. PubMed ID: 33243380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of mitral valve repair with the MitraClip delivery system for patients with mitral regurgitation: a systematic review.
    Rezapour A; Azari S; Arabloo J; Pourasghari H; Behzadifar M; Alipour V; Omidi N; Sadeghian S; Aghajani H; Bragazzi NL
    Heart Fail Rev; 2021 May; 26(3):587-601. PubMed ID: 33230582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EVEREST II high risk study based UK cost-effectiveness analysis of MitraClip® in patients with severe mitral regurgitation ineligible for conventional repair/replacement surgery.
    Mealing S; Feldman T; Eaton J; Singh M; Scott DA
    J Med Econ; 2013 Nov; 16(11):1317-26. PubMed ID: 24040937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.